Autoantibodies: disease markers

Luca Durelli MD (Dr. Durelli of the University of Torino has no relevant financial relationships to disclose.)
Anthony T Reder MD, editor. (Dr. Reder of the University of Chicago served on advisory boards and as a consultant for Bayer, Biogen Idec, Caremark Rx, Genentech, Genzyme, Novartis, Questcor/Malinkrodt, Serono, and Teva-Marion.)
Originally released December 19, 2015; last updated January 30, 2017; expires January 30, 2020

Overview

The number of diseases of the central or peripheral nervous system with a possible immune pathogenesis is increasing. Autoreactive antibodies may be directly responsible for the disease process or represent an epiphenomenon, without having a specific pathogenic role. In several diseases, their detection may be useful for the diagnosis. Autoreactive antibodies can eventually occur in paraneoplastic neurologic disorders. These antibodies might be useful for the diagnosis, too. However, they are also sometimes highly specific for a particular cancer and can help identify it at a stage before it is clinically overt, potentially leading to early successful therapy. Testing autoreactive antibodies might often be quite expensive. It is, therefore, important to know their sensitivity and specificity for the diagnosis or the possibly associated cancer in order to avoid useless tests. The reliability of the techniques used for antibody detection is also reviewed in this article.

Key points

 

• Autoreactive antibodies against central or peripheral nervous system antigens may be useful for the diagnosis of several neurologic diseases.

 

• In paraneoplastic neurologic disorders, their detection can also help identify an associated cancer at a stage before it is clinically overt, potentially leading to early successful therapy.

 

• Testing autoreactive antibodies might often be quite expensive.

 

• The sensitivity and specificity and the reliability of the commercially used techniques is important to evaluate in order to avoid useless tests.

Historical note and terminology

Autoreactive antibodies occur in a variety of neurologic disorders involving the central and peripheral nervous system. These antibodies may be directly responsible for the disease process or represent an epiphenomenon, without having a specific pathogenic role. The role of autoreactive autoantibodies is well-established in the pathogenesis of neuromuscular junction disorders such as myasthenia gravis and Lambert-Eaton myasthenic syndrome. Myasthenia gravis was first proposed as an autoimmune disorder by Simpson in 1960 (Simpson 1960). The association of anti-acetylcholine receptor (anti-AChR) antibodies with myasthenia gravis was first reported in the 1970s (Almon et al 1974). The presence of antibodies to a defined antigen specific to the disease process, clinical response to immunomodulatory therapy, and transmission of the disease to animals by passive transfer of immunoglobulins provide the evidence for antibody-mediated autoimmune mechanisms in this and in other neurologic disorders of the peripheral nervous system.

In the CNS, however, the pathogenic role of autoantibodies is not as well-defined and relies on their temporal relationship with the disease onset and the response to immunological therapies. The CNS disorders associated with autoreactive antibodies can be divided into those with known autoantigens, such as neuromyelitis optica with circulating antibodies to aquaporin-4 (Lennon et al 2005). Similar to myasthenia gravis, there are some patients in whom the association is tight and others in whom no antibodies are identified, despite a typical clinical picture. There are other disorders in which no specific antigen has yet been identified, such as multiple sclerosis (Lang et al 2003). A variety of autoreactive antibodies, including anticardiolipin, antinuclear, and antithyroid antibodies, which are usually associated with specific vasculitic or systemic syndromes, may occur in multiple sclerosis patients. Autoimmune diseases do not seem to occur with higher frequency in patients with multiple sclerosis and their family members (Ramagopalan et al 2007).

Autoantibodies against central or peripheral nervous system antigens can, eventually, occur in paraneoplastic neurologic disorders. Although a pathogenic role for autoantibodies has been established only for some paraneoplastic neurologic disorders, the presence of autoantibodies can be extremely important in the diagnostic workup. In fact, the clinical symptoms and antibodies associated with the paraneoplastic neurologic disorders precede the detection of a tumor by several months in almost 80% of patients, and positron emission tomography might detect a tumor or tumor recurrence in 90% of antibody-positive paraneoplastic neurologic disorder patients (Linke et al 2004; Honnorat and Antoine 2007). These antibodies are sometimes highly specific for a particular cancer and can help identify it at a stage before it is clinically overt, potentially leading to early successful therapy.

This article evaluates the usefulness of autoantibody testing for the diagnosis of neurologic diseases, reviewing the sensitivity and specificity of autoantibody testing. When sensitivity and specificity are indicated or can be calculated from the data of relevant papers, the number of patients and healthy controls or other neurologic disease patients will also be indicated to show the reliability.

Autoantibodies are detected with different immunoassays.

Tissue-based assays. Patients' antibodies are identified on brain tissue of rodents or primates. The antigen-antibody complex is stained with anti-human-IgG chemically linked to a fluorophore (indirect immunofluorescence) or conjugated to an enzyme, such as peroxidase, that can catalyze a color-producing reaction (indirect immunohistochemistry).

Immunoblot. Antibodies are identified as specific bands. Patients' antibodies are separated through gel electrophoresis by size, charge, or other differences in individual proteins. Separated antibodies are then transferred onto a nitrocellulose membrane and are identified by specific antibodies. The antigen-antibody complex is stained with peroxidase-conjugated anti-human-IgG.

Cell-based assays. Patients' antibodies are identified on suitable cell lines (such as HEK293 cells) that are transfected with an eukaryotic expression vector (plasmid) encoding the antigen.

Enzyme-linked immunosorbent assay (ELISA). A recombinant antigen is immobilized on a solid support and the detection antibody is added, forming a complex with the antigen. The antigen-antibody complex is, then, stained with peroxidase-conjugated anti-human-IgG. This technique allows the determination of antibody titer.

When an autoantibody test is useful for a disease diagnosis, the most relevant technique for each test will be also indicated. This will provide clinicians with important information on autoantibodies that are really useful in the correct diagnosis.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.